No valuation for uMed (Pharmaceuticals and Biotechnology) is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($18.1M) and the funding record below are the closest available signals.
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for uMed (Pharmaceuticals and Biotechnology)
- ·The full record, as it builds
Funding history
No funding rounds for uMed (Pharmaceuticals and Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
How uMed (Pharmaceuticals and Biotechnology)'s valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For uMed (Pharmaceuticals and Biotechnology), too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has uMed (Pharmaceuticals and Biotechnology) raised?
- uMed (Pharmaceuticals and Biotechnology) has raised $18.1M in total funding across its recorded rounds.